Acquisitions: Millipore strengthens the Chemicals business Audited

On July 14, 2010, Merck successfully completed the acquisition of Millipore Corporation, a leading life science company based in Billerica, Massachusetts, USA. The Millipore companies were then consolidated in the financial statements of the Merck Group for the first time. The total volume of the transaction was EUR 5,137 million. This includes payments amounting to EUR 4,612 million for the outstanding shares as well as existing options from stock option plans and payments of EUR 525 million to repurchase an outstanding convertible bond that had been issued by Millipore.

On February 28, 2010, Merck announced its offer to acquire all outstanding Millipore shares for USD 107 in cash per share of Millipore common stock. The closing followed the approval of the acquisition by Millipore’s shareholders at a special meeting held on June 3, 2010, and the satisfaction of other customary conditions, including antitrust clearance in the United States and Europe. Millipore was delisted from the New York Stock Exchange on July 26, 2010. Likewise, an application for deregistration from the U.S. Securities and Exchange Commission (SEC) was filed on July 26, 2010. The deregistration took effect on October 13, 2010.